


PHARMACEUTICAL 2022

CytoDyn Inc. Rank 410 of 475







PHARMACEUTICAL 2022

CytoDyn Inc. Rank 410 of 475



The relative strengths and weaknesses of CytoDyn Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CytoDyn Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 149% points. The greatest weakness of CytoDyn Inc. is the variable Net Income, reducing the Economic Capital Ratio by 188% points.

The company's Economic Capital Ratio, given in the ranking table, is -457%, being 180% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	129,581
Cost of Goods Sold	0
Intangible Assets	1,653
Liabilities, Current	152,546
Liabilities, Non-Current	552
Other Assets	712
Other Compr. Net Income	0
Other Expenses	31,402
Other Liabilities	0
Other Net Income	-30,522
Property and Equipment	134
Research and Development	58,430
Revenues	0
Selling, General and Administrative Expense	34,320

Output Variable	Value in 1000 USD
Assets	132,080
Liabilities	153,098
Expenses	124,152
Stockholders Equity	-21,018
Net Income	-154,674
Comprehensive Net Income	-154,674
Economic Capital Ratio	-457%